Investigational drug · Phase 2
LBS-007
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Relapsed or Resistant Acute Leukaemias.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "LBS-007"
First trial start
2023
Jul 20, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LBS-007", any sponsor or status.
Conditions studied
As listed on its trial records.
- Relapsed or Resistant Acute Leukaemias
Largest trials
Live from ClinicalTrials.gov: studies naming "LBS-007" as an intervention, largest first.
- The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute LeukaemiasRecruiting
Lin BioScience, IncIndustry
NCT05756322 · 90 participants (planned) · Start Jul 20, 2023 · Primary completion Dec 31, 2026
Drug: LBS-007 · For: Relapsed or Resistant Acute Leukaemias
Sites: Tampa, Florida; Chicago, Illinois; Fairway, Kansas · 17 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.